TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04919603

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced physical activity intervention
Description: the participants will take high-intensity exercise in accordance with High Intensity Interval Training (HIIT) prescriptions, with maximum heart rate and relative maximal oxygen uptake monitored. They will take both aerobic and resistance training exercise consecutively, and total training time will be expected to reach at least 150 minutes per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard education
Description: the participants will receive no extra intervention but diabetes health education, which will be carried out in large classrooms, in groups, and over the telephone. The education is mainly consisted of instructions on diabetes prevention according to \< Guidelines for prevention and treatment of type 2 diabetes in China (2017 edition)
Study: NCT05018676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARX788
Description: 1.5 mgkg IV infusion on Day 1 of each 21-day treatment cycle.
Study: NCT05101759

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Comprehensive Geriatric Assessment
Description: A systematic reassessment of geriatric parameters will be performed at 3 and 6 months post-inclusion.
Study: NCT06491017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MI-E Intervention protocol
Description: The endotracheal tube cuff will be inflated to 40 cmH2O and MI-E device will be used to deliver MI-E in automatic mode, with 4 sets of 5 respiratory cycles each and a 1-minute interval between each set.~Before initiation of the MI-E intervention protocol, the investigators will carry out a short-period test to find the appropriate MI-E settings to achieve inspiratory volumes of ≥1 liter and PEF ≥80 L/min. Concretely, inspiratory and expiratory time will always be set at 4 seconds and 2 seconds, respectively, and inspiratory flow will always be in slow mode. Once the appropriate inspiratory pressure will be found, the expiratory pressure will be initially set to exceed in 30 cmH2O the inspiratory pressure and, if required, this will be increased by 5 cmH2O until achieving a PEF ≥80 L/min with a maximum expiratory pressure of 70 cmH2O.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard MI-E setting
Description: Cough Assist E70 device (Philips Respironics, USA, Andover, Massachusetts) will be used to deliver MI-E in automatic mode, with 4 sets of 5 respiratory cycles each and a 1-minute interval between each set. During the 1-minute pause between sets, the patient will be reconnected to the ventilator to avoid desaturation and de-recruitment during procedures. PEEP will remain stable during the protocol.~The standard MI-E setting will consist of in-expiratory pressures of +40/-40 cmH2O, medium inspiratory flow, with 3 seconds and 2 seconds of in-expiratory time, respectively, and 1-second pause.
Study: NCT04520048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Determination of the UEMP levels
Description: Quantification of UEMP by flow cytometry in urine (10 ml) collected at 26 ± 2 week and 34th ± 2 week of amenorrhea.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aortic central pressure and the carotid-femoral pulse wave velocity
Description: Measurement of the aortic central arterial pressure (systolic and diastolic arterial pressure) by applanation tonometry, and the index of aortic increase by applanation tonometry, the carotid-femoral pulse wave velocity using the SphygmoCor® system (PWV Medical)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vascular biomarker assay
Description: Plasma angiogenic biomarker levels determination using an immunoassay, including circulating sFlt-1, circulating PIGF, sFlt-1 / PIGF ratio, circulating VEGF, circulating soluble endoglin (sEng), other biomarkers assessment, including anti-angiotensin II receptor (AT1), circulating copeptin, circulating interleukin 17 (IL-17), Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL), as well as CEMP and CEC quantification using flow cytometry.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Measurement of the uterine artery diameter
Description: This measurement is added to the routine examination of the uterine artery. Bi-dimensional ultrasound imaging with angio-Doppler allows the study of the artery as the blood flow velocity and vessel diameter. Uterine artery Doppler pulsatility index (UtA-PI), mean flow velocity and diameter measurement could be calculated with Doppler instrument with software could determine instantaneous true mean blood flow velocity. Measurement is made by placing the cursor from outer edge to outer edge of the artery adventitia, on a cross-section and taking the largest diameter
Study: NCT05120037

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial Direct Current Stimulation (tDCS) uses a mild electrical current to make small (or subtle) changes to how the brain works (or functions).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial Direct Current Stimulation (tDCS) uses a mild electrical current to make small (or subtle) changes to how the brain works (or functions).
Study: NCT06580340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AFA (Adapted Physical Activity)
Description: An exercise program to improve joint mobility, muscle strength, static and dynamic balance, motor coordination will be performed 2 times/week for 6 months.
Study: NCT05053880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT001
Description: Phase1b - Starting approximately 2 weeks prior to the scheduled surgery, patient will receive an assigned dose of ACT001 by mouth in combination with a single dose of 200 mg pembrolizumab via an intravenous (IV-through a tube in vain) infusion in the clinic. Then patient will self administer ACT001 capsules twice daily by mouth, at the dose to which patient is assigned, until the evening prior to scheduled surgery. Patient will then undergo surgery to remove all or part of tumor. This a standard 3+3 dose escalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT001 + Pembrolizumab
Description: Phase 2a - Starting approximately 2 weeks prior to the scheduled surgery, patient will receive a single dose of 200 mg pembrolizumab via an intravenous (IV) infusion in the clinic (an IV infusion means the drug will be delivered through a tube in your vein). Patient will then self-administer ACT001 capsules twice daily by mouth, at the dose to which patient is assigned, until the evening prior to scheduled surgery. Patient then will undergo surgery to remove all or part of tumor.
Study: NCT05090943

Intervention type: OTHER
Intervention: QOL to be completed by the participant
Description: The scales (PUTS, OCI, TS-QOL, ASRS, GAD-7, PHQ9, TAPS) to be completed by the participant
Study: NCT04812314

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will complete a moderate intensity continuous exercise 4 days/week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No exercise
Description: Participants will remain sedentary throughout the duration of the study.
Study: NCT05485480

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional opioid-based group
Description: In addition to propofol as a hypnotic and rocuronium as a muscle relaxant, patients in the conventional opioid-based group will receive the following drugs: Remifentanil and Fentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: opioid-sparing group
Description: In addition to propofol as a hypnotic and rocuronium as a muscle relaxant, patients in the opioid-sparing group will receive Ketamine, Fentanyl, Lidocaine, Magnesium, Clonidine, Remifentanil
Study: NCT04700553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Localized muscle vibration
Description: All patients in both experimental and control groups received CPT protocol consisted of 30 minutes of manual resistance exercise (3 sets/10 repetitions each for knee extensors and flexors) and 30 minutes of treadmill training, short breaks (1-5 minutes) were allowed, depending on the patient tolerance. The training was conducted for 3 days per week for 8 weeks. The patients in CPT+LMV experimental group received localized muscle vibration at the end of each CPT session. The LMV was applied for 5 minutes perpendicularly along quadriceps muscle fibers. The frequency set at 30 Hz, amplitude of 2 mm.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional physiotherapy intervention
Description: All patients in both experimental and control groups received CPT protocol consisted of 30 minutes of manual resistance exercise (3 sets/10 repetitions each for knee extensors and flexors) and 30 minutes of treadmill training, short breaks (1-5 minutes) were allowed, depending on the patient tolerance. The training was conducted for 3 days per week for 8 weeks. The patients in CPT+LMV experimental group received localized muscle vibration at the end of each CPT session. The LMV was applied for 5 minutes perpendicularly along quadriceps muscle fibers. The frequency set at 30 Hz, amplitude of 2 mm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy intervention
Description: All patients in both experimental and control groups received CPT protocol consisted of 30 minutes of manual resistance exercise (3 sets/10 repetitions each for knee extensors and flexors) and 30 minutes of treadmill training, short breaks (1-5 minutes) were allowed, depending on the patient tolerance. The training was conducted for 3 days per week for 8 weeks. The patients in CPT+LMV experimental group received localized muscle vibration at the end of each CPT session. The LMV was applied for 5 minutes perpendicularly along quadriceps muscle fibers. The frequency set at 30 Hz, amplitude of 2 mm.
Study: NCT05451667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YJ001 for Spray Use
Description: YJ001 (active ingredient)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YJ001 for Spray Use
Description: YJ001 (active ingredient)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YJ001 for Spray Use
Description: YJ001 (active ingredient)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YJ001 for Spray Use
Description: YJ001 (active ingredient)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of YJ001 for Spray Use
Description: Hydroxypropyl Methylcellulose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of YJ001 for Spray Use
Description: Hydroxypropyl Methylcellulose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of YJ001 for Spray Use
Description: Hydroxypropyl Methylcellulose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of YJ001 for Spray Use
Description: Hydroxypropyl Methylcellulose
Study: NCT05986045

Intervention type: OTHER
Intervention: Quality of Life
Description: ENHANCE will collect natural history on all children with cystic fibrosis who are enrolled over a 5 year period

Intervention type: OTHER
Intervention: Quality of Life
Description: ENHANCE will collect natural history on all children with cystic fibrosis who are enrolled over a 5 year period

Intervention type: OTHER
Intervention: Quality of Life
Description: ENHANCE will collect natural history on all children with cystic fibrosis who are enrolled over a 5 year period
Study: NCT06136104

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixhers HERTIME
Description: A daily self-administered powder supplement packet mixed into water.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A daily self-administered powder placebo supplement packet mixed into water.
Study: NCT05590442

Intervention type: OTHER
Intervention: Tests
Description: Cognitive assessments and olfactory tests

Intervention type: OTHER
Intervention: Tests
Description: Cognitive assessments and olfactory tests
Study: NCT05335200

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: (S)-[18F]FBFP PET/CT
Description: Patients will be intravenously injected with 185-370MBq (S)-\[18F\]FBFP and undergo serial whole-body PET/CT scans at multiple time points (5min, 15min, 30min, 45min, 1h, 2h, 4h). Safety assessment and tolerability of the study will be conducted.
Study: NCT05145543

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9%
Description: 0.9 NaCl % (Saline) (5 ml) will be applied

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine Hydrochloride
Description: 0.25 % levobupivacaine (5 ml) will be applied.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine Hydrochloride
Description: 0.25 % levobupivacaine (5 ml) will be applied.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine Hydrochloride
Description: 0.25 % levobupivacaine (5 ml) will be applied.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: fentanyl plus 0.25 % levobupivacaine (5 ml) will be applied.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone plus levobupivacaine (5 ml) will be applied.
Study: NCT05398796

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA -1215
Description: mRNA-1215 is a novel mRNA vaccine that encodes for the secreted prefusion stabilized F component covalently linked to G monomer (pre-F/G) of Malaysian strain NiV, resulting in a post-expression trimerization.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA -1215
Description: mRNA-1215 is a novel mRNA vaccine that encodes for the secreted prefusion stabilized F component covalently linked to G monomer (pre-F/G) of Malaysian strain NiV, resulting in a post-expression trimerization.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA -1215
Description: mRNA-1215 is a novel mRNA vaccine that encodes for the secreted prefusion stabilized F component covalently linked to G monomer (pre-F/G) of Malaysian strain NiV, resulting in a post-expression trimerization.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA -1215
Description: mRNA-1215 is a novel mRNA vaccine that encodes for the secreted prefusion stabilized F component covalently linked to G monomer (pre-F/G) of Malaysian strain NiV, resulting in a post-expression trimerization.
Study: NCT05848544

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Very low-calorie ketogenic diet for patients with symptomatic knee osteoarthritis
Description: A personalized very low-calorie ketogenic diet will be prepared for each patient by specialized dietitians using a combination of commercially-available ketogenic preparations and patient's handmade prepared meals

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Very low-calorie ketogenic diet for patients with fibromyalgia
Description: A personalized very low-calorie ketogenic diet will be prepared for each patient by specialized dietitians using a combination of commercially-available ketogenic preparations and patient's handmade prepared meals
Study: NCT05024656

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AmnioExcel Plus Amniotic Membrane
Description: AmnioExcel® Plus will be applied weekly, in conjunction with SOC, if the ulcer remains open, or up to and including Week 11, whichever comes first.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: The dressings, materials, and appliances used in accordance with institutional protocol or professional clinical judgement.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The dressings, materials, and appliances used in accordance with institutional protocol or professional clinical judgement.
Study: NCT04995263

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sueña component 1: Sleep Hygiene Promotion
Description: The nursery staff will be instructed to promote sleep hygiene. Nurse technicians will: inform patients of the efforts to ensure a healthy sleep environment, verify the minimization of light and noise after 23:00 PM, favour natural light after 07:00 AM, and foment patient's activities and participation in group therapy. Nurses will: reduce sleep interruptions to a minimum, to only perform actions (i.e. blood testing, clinical controls, medicine administration) deemed strictly necessary between 23:00 PM and 07:00 AM. A list of commonly used medications with their pharmacodynamic and pharmacokinetic properties tailored by a pharmaceutical chemist will be provided, to ensure optimal medication administration while protecting the guaranteed sleep hours, to be coordinated with the treating physician.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sueña component 1: Sleep Hygiene Promotion
Description: The nursery staff will be instructed to promote sleep hygiene. Nurse technicians will: inform patients of the efforts to ensure a healthy sleep environment, verify the minimization of light and noise after 23:00 PM, favour natural light after 07:00 AM, and foment patient's activities and participation in group therapy. Nurses will: reduce sleep interruptions to a minimum, to only perform actions (i.e. blood testing, clinical controls, medicine administration) deemed strictly necessary between 23:00 PM and 07:00 AM. A list of commonly used medications with their pharmacodynamic and pharmacokinetic properties tailored by a pharmaceutical chemist will be provided, to ensure optimal medication administration while protecting the guaranteed sleep hours, to be coordinated with the treating physician.
Study: NCT05435053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Every 2 weeks (3 mg/kg, maximum of 240 mg) for up to 24 weeks~Nivolumab is an immune checkpoint inhibitor (PD-1-inhibitor).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Description: Percutaneous ablation of a primary in-situ (or locally-recurrent) or metastatic lesion.~Irreversible electroporation is delivered through the NanoKnife system (AngioDynamics, New York, USA). The system is FDA-approved for medical use.
Study: NCT05780086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30% icodextrin and 10% dextrose
Description: Dwell time of 24 hours using a 500 ml sodium-free peritoneal dialysis solution based on 30% icodextrin and 10% dextrose
Study: NCT06225661

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAFE Intervention
Description: Manualized individual youth and family psychotherapeutic intervention. Weekly individual and family sessions with a therapist for 6 weeks. Participants will continue to receive usual care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NAV (Telephone Navigation)
Description: Weekly telephone contact with parents regarding participant health care utilization. Referrals to community mental health resources provided as needed. Participants will continue to receive usual care.
Study: NCT04273997

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole 10% ointment
Description: Metronidazole 10% ointment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ointment
Description: Placebo ointment
Study: NCT06355726

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma Exchange
Description: Plasma exchange session will be done on alternate day to a maximum of 5 sessions. PLEX will be discontinued if the patients Shows sustained clinical improvement, Receive liver transplantation, Refuses further PLEX session,no improvement in clinical condition and Intolerant to PLEX procedure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment
Study: NCT06129097

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Thyme honey mouthwash
Description: * Thyme honey will be applied as oral rinse.~* Based on this protocol, patients will have oral rinses (20 ml of thyme honey diluted in 100 ml of purified water) 3 times per day.~* Patients will be instructed to perform thyme honey rinses in the oral mucosa.~* Patients will be instructed not to swallow the thyme honey oral rinse.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thyme honey mouthwash
Description: * Thyme honey will be applied as oral rinse.~* Based on this protocol, patients will have oral rinses (20 ml of thyme honey diluted in 100 ml of purified water) 3 times per day.~* Patients will be instructed to perform thyme honey rinses in the oral mucosa.~* Patients will be instructed not to swallow the thyme honey oral rinse.
Study: NCT05578677

Intervention type: OTHER
Group type: OTHER
Intervention: Biopsy technique
Description: * Using the turn-and-suction technique, the forceps cups are opened and the forceps is withdrawn against the tip of the endoscope. The tip is then directed toward the target ('turn'), and suction is applied ('suction') as the forceps is applied against the targeted mucosa and then closed.~* Endoscopists can obtain two biopsy specimens from a single passage of the conventional biopsy forceps instead of one. These techniques are called the 'double-biopsy method' and the 'single-biopsy method', respectively.

Intervention type: OTHER
Group type: OTHER
Intervention: Biopsy technique
Description: * Using the turn-and-suction technique, the forceps cups are opened and the forceps is withdrawn against the tip of the endoscope. The tip is then directed toward the target ('turn'), and suction is applied ('suction') as the forceps is applied against the targeted mucosa and then closed.~* Endoscopists can obtain two biopsy specimens from a single passage of the conventional biopsy forceps instead of one. These techniques are called the 'double-biopsy method' and the 'single-biopsy method', respectively.

Intervention type: OTHER
Group type: OTHER
Intervention: Biopsy technique
Description: * Using the turn-and-suction technique, the forceps cups are opened and the forceps is withdrawn against the tip of the endoscope. The tip is then directed toward the target ('turn'), and suction is applied ('suction') as the forceps is applied against the targeted mucosa and then closed.~* Endoscopists can obtain two biopsy specimens from a single passage of the conventional biopsy forceps instead of one. These techniques are called the 'double-biopsy method' and the 'single-biopsy method', respectively.

Intervention type: OTHER
Group type: OTHER
Intervention: Biopsy technique
Description: * Using the turn-and-suction technique, the forceps cups are opened and the forceps is withdrawn against the tip of the endoscope. The tip is then directed toward the target ('turn'), and suction is applied ('suction') as the forceps is applied against the targeted mucosa and then closed.~* Endoscopists can obtain two biopsy specimens from a single passage of the conventional biopsy forceps instead of one. These techniques are called the 'double-biopsy method' and the 'single-biopsy method', respectively.
Study: NCT04676724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3228836
Description: Participants will be administered GSK3228836.